| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 04/10/2003 | WO2003029245A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 04/10/2003 | WO2003029233A1 New sulfonamide derivatives as d3-receptor agonists |
| 04/10/2003 | WO2003029184A1 Diaryl ether derivative, addition salt thereof, and immunosuppressant |
| 04/10/2003 | WO2003028765A1 Injections for eye tissue containing drug bound to polyethylene glycol |
| 04/10/2003 | WO2003028736A2 Pharmaceutical preparations comprising alkyl phosphocholine compounds in liposomes which may be sterile-filtered or heat-sterilised |
| 04/10/2003 | WO2003028715A2 Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis |
| 04/10/2003 | WO2003028701A2 Liposomes containing (ether)lysolecithins |
| 04/10/2003 | WO2003028650A2 Benzimidazolidinone derivatives as muscarinic agents |
| 04/10/2003 | WO2003028527A2 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| 04/10/2003 | WO2002094830A8 Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists |
| 04/10/2003 | WO2002092064A3 Therapeutic method for inducing tolerance |
| 04/10/2003 | WO2002059083A3 Novel compounds |
| 04/10/2003 | WO2002028889A3 Haemophilus influenzae antigens and corresponding dna fragments |
| 04/10/2003 | WO2002008396A3 Human proteases |
| 04/10/2003 | US20030069430 Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects |
| 04/10/2003 | US20030069406 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of blood disorders |
| 04/10/2003 | US20030069312 Nitromethyl ketones, process for preparing them and compositions containing them |
| 04/10/2003 | US20030069296 Central nervous system disorders |
| 04/10/2003 | US20030069294 Alpha-substituted carboxylic acid derivatives |
| 04/10/2003 | US20030069292 Central nervous system disorders; anticonvulsants |
| 04/10/2003 | US20030069290 Substituted-heteroaryl-7-aza[2.2.1] bycycloheptanes for the treatment of desease |
| 04/10/2003 | US20030069287 Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors |
| 04/10/2003 | US20030069286 Vision defects |
| 04/10/2003 | US20030069260 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
| 04/10/2003 | US20030069249 Analgesics; central nervous system disorders |
| 04/10/2003 | US20030069243 Novel substituted imidazole compounds |
| 04/10/2003 | US20030069235 Therapy for eye infections |
| 04/10/2003 | US20030068664 Monitoring effectiveness of preferential cancer immunotherapy; obtain mammal, administer immunotherapy, evaluate effectiveness of treatment |
| 04/10/2003 | US20030068640 Diagnosing vision defects in mammals; obtain tissue sample, extract nucleotide sequences, detect mutaion in tigr allele, presence of mutation indicates vision defects |
| 04/10/2003 | US20030068294 Includes at least one keratolytic and cerumenilytic cleaning agent, one bactericide agent, one yeast control agent and one anti-irritant and anti-pruriginous agent; for ear hygiene and for the prevention of otitis in dogs and cats |
| 04/10/2003 | US20030068250 For contact lenses |
| 04/10/2003 | CA2462112A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 04/10/2003 | CA2461099A1 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| 04/10/2003 | CA2457647A1 Benzimidazolidinone derivatives as muscarinic agents |
| 04/09/2003 | EP1300468A2 TRNA synthetase |
| 04/09/2003 | EP1300407A1 Carbamates derived from arylalkylamines |
| 04/09/2003 | EP1300151A2 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| 04/09/2003 | EP1300150A2 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| 04/09/2003 | EP1300149A2 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| 04/09/2003 | EP1300148A2 Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
| 04/09/2003 | EP1299545A2 Drug metabolizing enzymes |
| 04/09/2003 | EP1299538A2 Secreted proteins |
| 04/09/2003 | EP1299415A1 Chemokine receptor modulators, production and use |
| 04/09/2003 | EP1299412A2 Protein modification and maintenance molecules |
| 04/09/2003 | EP1299385A2 Fused cyclic modulators of nuclear hormone receptor function |
| 04/09/2003 | EP1299383A1 Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders |
| 04/09/2003 | EP1299374A1 Novel non-psychotropic cannabinoids |
| 04/09/2003 | EP1299373A1 Cyclic substituted aminomethyl compounds and medicaments containing said compounds |
| 04/09/2003 | EP1299351A1 Novel aryl, alkenyl, and alkynl 4-dedimethylaminotetracycline derivatives |
| 04/09/2003 | EP1299157A1 Composition and applicator for topical substance delivery |
| 04/09/2003 | EP1299123A2 Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
| 04/09/2003 | EP1299112A2 Compositions for treating eye discomfort, containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 04/09/2003 | EP1220844B1 Aryl sulfonamide-substituted benzimidazol derivatives thereof as tryptase inhibitors |
| 04/09/2003 | EP0996612B1 Aliphatic propargylamines as cellular rescue agents |
| 04/09/2003 | CN1409726A Type I cytokine receptor TCCR |
| 04/09/2003 | CN1409722A Antagonists of BMP and TGF beta signalling pathway |
| 04/09/2003 | CN1409708A 酪氨酸激酶抑制剂 Tyrosine kinase inhibitor |
| 04/09/2003 | CN1409639A TNF-alpha antagonist and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder |
| 04/09/2003 | CN1408431A Gene engineering medicine for curing diseases relative to vascularization |
| 04/09/2003 | CN1408418A High stable anti-cataract medicine |
| 04/09/2003 | CN1408369A Bear gall eye drops for improving eyesight and its producing method |
| 04/09/2003 | CN1105114C Sulfonyl divalent aryl alpha-hydroxy-iso-hydroximic acid compounds |
| 04/09/2003 | CN1105101C Beta-sultonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| 04/09/2003 | CN1104908C Improved vision through photodynamic therapy of eye |
| 04/09/2003 | CN1104898C Ocular tension depressant |
| 04/09/2003 | CN1104896C RAR-gamma antagonist ligand or RAR-alpha agonist ligand as apoptosis inhibitor |
| 04/09/2003 | CN1104892C Method for curing tinnitus by nerve protecting agent |
| 04/08/2003 | US6545182 Methods and compositions for modulating alpha adrenergic receptor activity |
| 04/08/2003 | US6545058 Contains terpenoid as active ingredient |
| 04/08/2003 | US6545050 Aryl sulphonamide amino acid esters and analogues |
| 04/08/2003 | US6545049 E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof |
| 04/08/2003 | US6545045 Administering to an effected eye rioprostil, SC 46275, enisoprost, misoprostol, nocloprost, enprostil, 11-deoxy-16-16-dimethyl- PGE2, and 16,16-dimethyl-PGE2, or esters or cationic salts thereof |
| 04/08/2003 | US6545038 Heterocyclic metalloprotease inhibitors |
| 04/08/2003 | US6545036 Potassium channel blockers; neuroprotectants, glaucoma, n-benzoyl indole compounds with 3-acylureamethyl group |
| 04/08/2003 | US6545023 For treating rheumatoid arthritis; for examle, 1-(4-(4-fluorophenyl)piperidin-1-yl),3-(2-methoxy-4 -chlorobenzylaminocarbonyl),3-isopropyl-cyclopentane |
| 04/08/2003 | US6545018 Oxamic acids and derivatives as thyroid receptor ligands |
| 04/08/2003 | US6545005 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 04/08/2003 | US6545003 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 04/08/2003 | US6545002 Treating asthma, diarrhea, insulin resistance, diabetes, ischemia/reprefusion injuries, diabetic retinopathy or hyperbaric oxygen-induced retinopathy |
| 04/08/2003 | US6544998 Combination of gaba agonists and sorbitol dehydrogenase inhibitors |
| 04/08/2003 | US6544988 Tyrosine kinase inhibitors |
| 04/08/2003 | US6544987 Compounds, compositions, and methods for stimulating neuronal growth and elongation |
| 04/08/2003 | US6544544 Compound which disrupts microtubule function and polymeric carrier, with proviso that polymeric carrier is not a capsule |
| 04/08/2003 | US6544193 Noninvasive measurement of chemical substances |
| 04/08/2003 | CA2184584C Vascular endothelial growth factor 2 |
| 04/08/2003 | CA2061907C Treatment of ocular hypertension with a synergistic combination |
| 04/08/2003 | CA2053216C Saturated hydroxyalkylquinoline acids as leukotriene antagonists |
| 04/07/2003 | WO2002032866A1 (4-acylaminopiperidin-1-yl) acetamides as neurokinin antagonists |
| 04/03/2003 | WO2003027285A1 Dna sequences for human angiogenesis genes |
| 04/03/2003 | WO2003027275A1 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| 04/03/2003 | WO2003027263A2 Proteins associated with cell growth, differentiation, and death |
| 04/03/2003 | WO2003027116A2 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives |
| 04/03/2003 | WO2003027115A1 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders |
| 04/03/2003 | WO2003027090A2 Bicyclic heterocycles as rxr ligands |
| 04/03/2003 | WO2003027080A1 3-substituted-4-pyrimidone derivatives |
| 04/03/2003 | WO2003027076A2 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity |
| 04/03/2003 | WO2003027075A2 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation |
| 04/03/2003 | WO2003026744A1 The use of epothilones and analogs in conjunction with ophthalmic surgery |
| 04/03/2003 | WO2003026671A1 Method of treating middle ear infections |
| 04/03/2003 | WO2003026668A1 Ophthalmologic treatment methods using selective inos inhibitors |